1. Bergaptol inhibits glioma cell proliferation and induces apoptosis via STAT3/Bcl-2 pathway.
- Author
-
Huang H, Zhang J, Wu J, Du C, Zheng B, Guo Z, Chen L, Zhang D, and Liu L
- Subjects
- Animals, Humans, Mice, Cell Line, Tumor, Signal Transduction drug effects, Xenograft Model Antitumor Assays, Furocoumarins pharmacology, Mice, Inbred BALB C, Cell Movement drug effects, Flavanones, STAT3 Transcription Factor metabolism, Cell Proliferation drug effects, Apoptosis drug effects, Proto-Oncogene Proteins c-bcl-2 metabolism, Mice, Nude, Brain Neoplasms drug therapy, Brain Neoplasms pathology, Brain Neoplasms metabolism, Glioma drug therapy, Glioma pathology, Glioma metabolism
- Abstract
Glioblastoma (GBM) is the most common primary malignant brain tumour and lacks therapeutic options with significant effects. The aberrant activation of STAT3 is a critical factor in glioma progression via activating multiple signalling pathways that promote glioma. Among them, the antiapoptotic gene Bcl-2 could be upregulated by p-STAT3, which is an important reason for the continuous proliferation of glioma. We previously reported that bergaptol, a natural furanocoumarin widely found in citrus products, exerts antineuroinflammatory effects by inhibiting the overactivation of STAT3. Here, we aimed to evaluate whether bergaptol could promote glioma apoptosis by inhibiting the STAT3/Bcl-2 pathway. This study found that bergaptol inhibited the proliferation and migration of GBM cell lines (U87 and A172) and promoted apoptosis in vitro. We also found that bergaptol significantly inhibited the STAT3/Bcl-2 pathway in GBM cells. U87 cells were implanted intracranially into nude mice to establish a glioma model, and glioma-bearing mice were treated with bergaptol (40 mg/kg). Bergaptol treatment significantly inhibited glioma growth and prolonged the glioma-bearing mice's survival time. In addition, bergaptol administration also significantly inhibited the STAT3/Bcl-2 pathway of tumour tissue in vivo. Overall, we found that bergaptol could effectively play an antiglioma role by inhibiting STAT3/Bcl-2 pathway, suggesting the potential efficacy of bergaptol in treating glioma., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF